Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway
1 Department of Haematology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, China
2 Department of Haematology, First Hospital of Quanzhou Affiliated Fujian Medical University, Quanzhou, Fujian, 36200, China
Cancer Cell International 2013, 13:25 doi:10.1186/1475-2867-13-25Published: 13 March 2013
Arsenic Trioxide (ATO) has shown remarkable efficacy for the treatment of multiple myeloma (MM). However, the mechanism by which ATO exerts its inhibitory effect on the proliferation of myeloma cells remains to be clarified. We study the inhibitory effect of ATO at various concentrations on the proliferation of the myeloma cell line RPMI 8226 and discussed the molecular mechanism of ATO on myeloma cell line. Our results proved that ATO had a significant dose-dependent and time-dependent inhibitory effect on the expressions of the Notch receptor (Notch1) and Notch ligand (Jag2). Data from the real-time PCR assay showed that the mRNA expression levels of the Jag2 gene and its downstream gene Hes1 were both significantly down-regulated after the myeloma cells were treated with ATO while the expression of the tumor suppressor gene PTEN was up-regulated. These results elucidated the molecular mechanism underlying the ATO mediated inhibition of myeloma cell proliferation. This is the first report on the anti-myeloma activity in myeloma cells through inhibition of the Notch signaling pathway.